Last reviewed · How we verify

Mulberry Leaf Extract

University of Mississippi Medical Center · FDA-approved active Small molecule

Mulberry leaf extract inhibits alpha-glucosidase enzymes in the small intestine, slowing carbohydrate digestion and reducing postprandial blood glucose levels.

Mulberry leaf extract inhibits alpha-glucosidase enzymes in the small intestine, slowing carbohydrate digestion and reducing postprandial blood glucose levels. Used for Type 2 diabetes mellitus, Postprandial hyperglycemia.

At a glance

Generic nameMulberry Leaf Extract
Also known asMulberry, Morus indica L., Morus alba
SponsorUniversity of Mississippi Medical Center
Drug classAlpha-glucosidase inhibitor
TargetAlpha-glucosidase enzymes (intestinal disaccharidases)
ModalitySmall molecule
Therapeutic areaEndocrinology / Diabetes
PhaseFDA-approved

Mechanism of action

The extract contains iminosugars (particularly 1-deoxynojirimycin) and polyphenols that competitively inhibit intestinal enzymes responsible for breaking down disaccharides and complex carbohydrates. This delays glucose absorption, resulting in lower postprandial glucose spikes and improved glycemic control. The mechanism also involves potential improvements in insulin sensitivity and lipid metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: